GLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ GenesGLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ Genes
ProtocolProductsStacksPeptide ClassesLooks MaxxingGuidesResearchShop Stacks →
Guide7 min read2026-04-09

IGF-1 LR3: The IGFBP-Resistant Research Analog

IGF-1 LR3 solves the native IGF-1 binding problem through a 13-amino-acid N-terminal extension. Here is why that matters for research.

The Binding Problem LR3 Solves

Native IGF-1 in circulation is approximately 99% bound to IGFBPs (IGF binding proteins). Free IGF-1 is what reaches and activates the IGF-1 receptor — which means the IGFBPs act as a buffer that damps signal amplitude. Research on IGF-1 pharmacology has to account for this buffer or bypass it.

The LR3 modification bypasses it. The research-grade compound is available as IGF-1 LR3 1mg.

The Long R3 Modification

IGF-1 LR3 carries two modifications vs native IGF-1:

  1. 13-amino-acid N-terminal extension — disrupts IGFBP binding
  2. Arg³ substitution — further reduces IGFBP-3 affinity

The net result is a compound that maintains IGF-1R affinity while reducing IGFBP binding by orders of magnitude. More of the dosed compound reaches the receptor.

Downstream IGF-1R Cascade

IGF-1R is a tyrosine kinase receptor. Activation initiates two primary signaling branches:

  • PI3K/Akt: Protein synthesis, survival signaling, glucose uptake
  • MAPK/Ras: Cell proliferation, gene expression modulation

The research-relevant outcome markers are:

  • Ribosomal S6 kinase activation (protein synthesis)
  • GLUT4 translocation (glucose handling)
  • Myogenic differentiation markers

Practical Implications for Research Protocols

  • Half-life ~20–30 hours — longer than native IGF-1 but shorter than albumin-bound compounds
  • Systemic vs local: Systemic dosing engages IGF-1R everywhere; site-specific research reduces systemic exposure
  • Receptor desensitization: Sustained activation can downregulate IGF-1R — cycling is a research design consideration

Research Context: The GH Axis

IGF-1 LR3 research sits downstream of GH axis research. A complete GH axis protocol typically engages:

  1. Upstream: CJC-1295 or Sermorelin (GHRH receptor)
  2. Middle: Ipamorelin or similar (ghrelin receptor / GH secretagogue)
  3. Downstream: IGF-1 LR3 (IGF-1R direct activation)

Isolating the IGF-1R contribution requires studying LR3 alone; isolating upstream GH biology requires studying CJC/Ipamorelin alone. Combined research asks how the axis behaves under full activation.

Sourcing IGF-1 LR3

Research-grade IGF-1 LR3 requires higher QC standards than many smaller peptides because folding and disulfide bond integrity are critical to IGF-1R affinity. >98% HPLC purity and mass spec verification are the standard. See IGF-1 LR3 1mg for the research-grade vial.

← Back to Guides